 |
 |
||||||||||||||
|
|
| OAPI Profile |
||||||||||
|
Driven to help our customers deliver better patient outcomes
Otsuka America
Pharmaceutical, Inc. (OAPI) is a growing healthcare company, with a
strong focus and commitment to neuroscience, oncology and hospital
therapies. OAPI is responsible for all
pharmaceutical and medical device commercial activities in North America and is part of the Otsuka Group
which is comprised of 153 companies and employs 36,000 employees
worldwide in 23 nations and regions throughout the world. OAPI has
corporate offices in Rockville, Maryland and Princeton, New Jersey and
employs over 500 pharmaceutical industry professionals. OAPI is supported by a
network of Otsuka research institutes around the world that focus on
pioneering and developing new treatments and indications. OAPI has built
a solid business foundation on Otsuka-developed products and continues
to build on this foundation to achieve its
corporate vision: A strong and highly competitive organization capable
of successfully launching our own products for better patient outcomes. In 2009, OAPI is taking on greater responsibility for driving the growth of ABILIFY® (aripiprazole) in the US by building a strong neuroscience organization to maximize growth within the psychiatric community. OAPI is also focused on growing its oncology, hospital, and device businesses.
Current Product Portfolio
Annual Sales Since 2004, our annual net sales have grown by 300%, with 2008 net sales exceeding $2.6 billion.
|
||||||||||
| * OAPI, OPDC and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd. 0109W-0602 |